Zentiva, a Czechia-based generics pharmaceutical company, announced on Friday that it has received the ESG Transparency Award 2025, presented by German market research organisation EUPD Group at the ESG Summit 2025.
The award aims to recognise companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.
EUPD Group said that Zentiva was awarded the Excellence Level of the ESG Transparency Award for its high degree of clarity, accessibility and transparency in sustainability reporting. This distinction places the company among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA